

Contents

Volume 23, 1989

Volume 23, Number 1

1989

CONTENTS

- | | | |
|---|----|--|
| Alick J. Munro | 1 | Developing Procedure at Clinical Investigation Units |
| David A. Carlin
Peter Palmer | 5 | Problems, Pitfalls, and Solutions to the Development of an International Clinical Database |
| Paolo E. Lucchelli
Francesco Gianese | 11 | Planning a Clinical Research Program for Global Use |
| Dorle Messerer
Joerg Hasford | 15 | Monitoring Multicenter Trials and its Impact on Trial Results |
| Bruce P. Greenberg
Chialing C. Yen
Richard C. Accomando | 21 | Tracking of Clinical Data for an International Environment |
| Klaus Stern
Juergen Lilienthal
Wilhelm Sauermann
Reinhard Zentgraf | 25 | Requirements on an Integrated DBMS for Data From Clinical Trials |
| Gian Marco Leali
Patrizia Pugnetti | 37 | A Protocol-Independent Database for Clinical Studies |
| Richard A. Boulding | 55 | Problems of Global Clinical Data Management |
| Roland Blomer | 65 | Practical Relevance of Relational Database Properties for Clinical Database Management |
| Christian Benichou
Gaby Danan | 71 | Lack of Definitions of Adverse Drug Reactions |
| Erika F. Nissman
Domenic G. Iezzoni | 75 | Report on a WHO ART-COSTART Translation Project |
| Donna K. Jackson
Susan Piasecki
Frank A. Adornato | 81 | Regulatory Perspective of Worldwide Marketing Authorization Applications |

David M. Cocchetto	87	Issues Regarding Compassionate Treatment With Investigational New Drugs
Jay H. Bauman Robert J. Fuentes	95	Drug Information at Glaxo Inc
Gérard B. Bailly Marc Pierredon Richard Rondel Lucien Steru Elie Szapiro	105	Phase IV and Europe
Steven R. Miola	117	Preparing an Individual Clinical Study Report
Mary Ellen Kitler	123	The Elderly in Clinical Trials: Regulatory Concerns
Eric van der Putten Hilary R. Franklin	139	Quality Control in Phase I-III Cancer Clinical Trials
Klaus Abt Iain T. R. Cockburn Albert Guelich P. Krupp	143	Evaluation of Adverse Drug Reactions by Means of the Life Table Method
Roger P. Nelson	151	Organization of Information Departments in the US Pharmaceutical Industry
Bams Abila	165	Efforts to Monitor Adverse Drug Reactions in Africa: A Case Study of Nigeria
	I	Software Survey Section

CONTENTS

**Computer-based Systems for Storage,
Reporting, and Analysis of Worldwide Postmarketing Drug Safety Data**

Harry A. Guess	169	Worldwide Drug Safety Information Processing — What's Ahead?
Linda Hostelley	171	Reporting and Tracking Spontaneous Adverse Experience Reports via a Computer Database
Fred Schneiweiss	179	Capture and Analysis of Spontaneous Adverse Event Data at A. H. Robins

- | | | |
|-----------------------------|-----|---|
| Win M. Castle | 183 | The ICI Approach: Possible Adverse Reaction Information System |
| John C. C. Talbot | 189 | Database Management and Reporting Systems — Foreign-based Companies: The Glaxo Approach |
| Hugh H. Tilson | 197 | <i>Discussion Panel:</i> Database Management and Reporting Systems of Foreign-based Companies |
| Lorely J. E. Maskell | 203 | Wellcome Group Computer-based System for Worldwide Adverse Drug Reaction Report Management |
| Judith M. Sills | 211 | World Health Organization Adverse Reaction Terminology Dictionary |
| Terry L. Gillum | 217 | The Merck Regulatory Dictionary: A Pragmatically Developed Drug Effects Vocabulary |
| Charles Anello | 221 | Electronic Submission of Periodic Reports |
| James C. Mannion | 225 | Turning Computer Reports Into Labeling Changes |
| Harry A. Guess | 231 | <i>Discussion Panel:</i> What Can Validly be Done with Spontaneous Adverse Drug Experience Reports? |

Additional Articles

- | | | |
|--|-----|---|
| H. C. Faulkner III
R. H. Farmen | 245 | Database Design and Management in a Pharmacokinetic Department |
| L. Edward Kirk
G. Edward Collins
Michael C. Joseph
Deborah Katz | 257 | Retrovir® (zidovudine): A Unique Drug Information Challenge |
| Steven J. Blumenthal | 267 | Discovery of the New Drug Therapies Based on the Study of Adverse Reactions |
| Martha M. Rumore
Jack M. Rosenberg | 273 | Comparison of Drug Information Practice in Hospitals and Industry |
| Alan M. Daly
Ronald A. Martin
Edward J. McGuire
Carlo J. Di Fonzo | 285 | A Microcomputer-based Data Acquisition and Reporting System for Clinical Pathology Data from Animal Drug Toxicology Studies |
| Frances E. Nolan | 297 | Computerization of the Pathology Application Area |
| David W. Gaylor | 303 | Estimation of Cancer Risk |

- | | | |
|--|-----|--|
| Marie A. Abate
Arthur I. Jacknowitz
James M. Shumway | 309 | Information Sources Utilized by Private Practice and University Physicians |
| Jacqueline Anne Sayers
Paul Blake | 321 | An Alternative Approach to Clinical Research Associate Training |
| Ingrida S. Sketris
Anne Bishop
Emily Somers
G. Ross Baker | 327 | Developing a Quality Assurance Program for Drug Information Requests Answered by Staff Pharmacists |
| Bams Abila | 335 | Drug Discovery: Need to Explore African Phytoresources |
| Elisabeth Poy
John Donahue | 339 | Quality Assurance of Clinical Trials and Good Clinical Practices in France |
| | I | Software Survey Section:
<i>Entrypoint 90</i> |

Volume 23, Number 3

1989

CONTENTS

- | | | |
|---|-----|---|
| Roger W. Croswell | 345 | Guest Editor's Note |
| | 347 | Preface |
| Roger W. Croswell
Alastair G. Ramsay | 349 | Welcome and Introduction |
| Roger W. Croswell | 353 | Session 1: A Brief Overview of the Similarities and Differences between the US and EEC Chemical and Pharmaceutical Requirements for Clinical Trials and for the Marketing Authorization/NDA |
| Anthony S. Angiuoli | 355 | Comparative Requirements for Initiating Clinical Trials (Including IND and CTC) |
| Roger W. Croswell | 365 | Questions and Answers: Session 1 |
| Kevin McKenna | 371 | An Overview and Comparison of the US and EEC Chemical and Pharmaceutical Requirements for the Marketing Authorization/New Drug Application |
| Roger W. Croswell | 379 | Initiation of Working Groups |

- | | | |
|-------------------------------------|-----|--|
| Charles S. Kumkumian | 391 | Session 2: Detailed Review of US and EEC Documentation Requirements for the Active Constituent |
| Charles S. Kumkumian | 393 | Requirements for the Active Constituent and Available Guidelines |
| George R. Wellman | 395 | The Active Constituent: US and EEC Requirements for Documenting the Method of Preparation, Control of Starting Materials and Intermediates, Control of the Final Bulk Product, and Batch Analyses (Including Those from Toxicology and Clinical Studies) to Support Proposed Impurity Limits |
| Charles S. Kumkumian | 405 | The Reference Standard: US and EEC Requirements for Documenting the Proof of Structure and Physical/Chemical Properties |
| M. O'Brien | 411 | US and EEC Requirements for Documenting the Stability of the Active Constituent |
| Richard Margerison | 417 | Recommendations for a Truly International Registration Dossier |
| Charles S. Kumkumian | 421 | Questions and Answers: Session 2 |
| Anthony C. Cartwright | 427 | Session 3: A Detailed Review of US and EEC Documentation Requirements for the Final Dosage Form and Available Guidelines |
| Klaus Salm
Arnold Urdang | 429 | The Dosage Form: US and EEC Requirements for Documenting the Method of Preparation and Control of Clinical Trials' Supplies and the Final Dosage Form Proposed for Marketing |
| Anthony C. Cartwright | 439 | Comments |
| G. R. Dukes
C. H. Bibart | 441 | The Dosage Form — US and EEC Requirements for Documenting Its Stability for Clinical Trials and Marketing |
| Anthony C. Cartwright | 449 | Questions and Answers: The Dosage Form Stability |
| J. Michael Morris | 453 | US and EEC Requirements for Documenting Process and Methods Validation |
| Karen Hoerlyk | 463 | The Final Dosage Form: Effectively Dealing with Differences in Local and National Requirements |
| Anthony C. Cartwright | 469 | Questions and Answers: Session 3 |

Yuan-yuan H. Chiu	477	Session 4: Review and Discussion of Special Chemical and Pharmaceutical Requirements in the US for Biotechnology Products
Huib Van de Donk	483	Effectively Dealing with the Special Chemical and Pharmaceutical Considerations in the US and EEC for Biotechnology Products – Part 1A
Birgit Praefke	495	Effectively Dealing with the Special Chemical and Pharmaceutical Considerations in the US and EEC for Biotechnology Products – Part 1B
Alan Dinner John Fose	501	Effectively Dealing with the Special Chemical and Pharmaceutical Considerations in the US and EEC for Biotechnology Products – Part 2
Yuan-yuan H. Chiu	511	Questions and Answers: Session 4
Alastair G. Ramsay	515	Working Group 1: The Active Constituent – A Model International Registration Dossier
Kevin McKenna	529	Working Group 2: The Final Dosage Form – A Model International Registration Dossier
Kevin McKenna	539	Report of the Working Group on "The Finished Dosage Form"
Anthony C. Cartwright Charles S. Kumkumian Klaus Salm	543	Summary and Closing Remarks: Where to from Here?
Harvey Gurien Gary M. Klee	545	Core Requirements for International Registration of Drugs (New Chemical Entities): Manufacturing and Controls
	561	Workshop Contributors
	I	Software Survey Section: <i>INQUIRE/Text</i>

CONTENTS

**Promotional and Marketing Activities:
Preapproval, Time of Approval, Postapproval**

Wayne L. Pines	563	Foreword
Wayne L. Pines	565	A Perspective on Pharmaceutical Marketing

- Lloyd Millstein** 571 Preparing to Market a New Product
- Gail R. Safian** 577 Marketing Issues in the Preapproval Stage
- Robert C. deGroof** 581 Research for a Marketing Plan
- William W. Vodra** 585 How the FDA Regulates Drug Promotion and Medical Education Before Drug Approval
- Kenneth R. Feather** 597 Preapproval Promotion: FDA's View
- John Chervokas** 601 Medical Advertising in the 1990s
- Thomas D'Alonzo** 605 Co-marketing as an Innovative Marketing Technique
- Joseph A. Romano** 609 Overview of Current Marketing Issues
- Tom Webber** 615 The Launch of Xanax
- Wendy Borow** 619 New Ideas in Medical Education: Medical TV
- Kenneth P. Berkowitz** 623 Perspectives on Promotional Regulations
- David G. Adams** 625 FDA Regulation of Promotion of Drugs: A Legal Primer
- Louis A. Morris** 635 Current FDA Policies on Drug Promotion
David Banks
- James H. Stewart** 641 Marketing to Managed Care Institutions
- Wayne I. Roe** 647 Reimbursement Planning for New Pharmaceuticals: Strategic Challenges in the 1990s
- Sheila Raviv** 653 Working with and through Third-party Groups
- Charles L. Fry** 657 Innovations in Drug Marketing
- Additional Articles**
- Judi Weissinger** 663 Considerations in the Development of Stereoisomeric Drugs: FDA Viewpoint
- Wesley Mark Todd** 669 Phase I Trials: Past, Present, and Future
- R. Vander Stichele** 673 Patient Package Inserts: The Belgian Experience
M. G. Bogaert with a Mandatory Program
- Albert Weissman** 679 On the Designation of Race in Clinical Pharmacology Reports

Robert W. Ashworth	687	IND Requirements for Biotechnology Products
George S. Hughes, Jr	693	Challenges in the Design of Phase I and Early Phase II Studies
Beverly M. De Vries	699	Recruitment of Volunteers for Phase I and Phase II Drug Development Studies
George S. Hughes, Jr		
Steven F. Francom		
J. S. Mohrland	705	Use of Microcomputers to Monitor an Offshore Phase I Clinical Trial
W. J. Bryan		
	709	Letters to the Editor
	I	Software Survey Section
	V	Volume 23 Contents and Author Index

